



FDA-approved small-molecule kinase inhibitors

Wu, Peng; Nielsen, Thomas E.; Clausen, Mads Hartvig

Published in:
Trends in Pharmacological Sciences

Link to article, DOI:
[10.1016/j.tips.2015.04.005](https://doi.org/10.1016/j.tips.2015.04.005)

Publication date:
2015

Document Version
Peer reviewed version

[Link back to DTU Orbit](#)

Citation (APA):
Wu, P., Nielsen, T. E., & Clausen, M. H. (2015). FDA-approved small-molecule kinase inhibitors. *Trends in Pharmacological Sciences*, 36(7), 422-439. <https://doi.org/10.1016/j.tips.2015.04.005>

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

1 **FDA Approved Small Molecule Kinase Inhibitors**

2 Peng Wu¹, Thomas E. Nielsen², and Mads H. Clausen^{1,3}

3 ¹ Department of Chemistry, Technical University of Denmark, Kgs. Lyngby DK-2800, Denmark

4 ² Protein and Peptide Chemistry, Novo Nordisk A/S, Måløv DK-2760, Denmark

5 ³ Center for Nanomedicine and Theranostics, Technical University of Denmark, Kgs. Lyngby DK-
6 2800, Denmark

7

8 Corresponding author: Peng Wu (penwu@kemi.dtu.dk)

1 **Abstract:**

2 Kinases have emerged as one of the most intensively pursued targets in current pharmacological
3 research, especially for cancer, due to their critical roles in cellular signaling. To date, the USA
4 Food and Drug Administration (FDA) has approved twenty-eight small molecule kinase inhibitors,
5 half of which were approved in the past three years. While the clinical data of these approved
6 molecules are widely presented and structure-activity relationship (SAR) has been reported for
7 individual molecules, an updated review that analyzes all approved molecules and summarizes
8 current achievements and trends in the field has yet to be found. Herein we present all approved
9 small molecule kinase inhibitors with an emphasis on binding mechanism and structural features,
10 summarize current challenges, and discuss future directions in this field.

11

12 **Keywords:**

13 cancer, protein kinase, lipid kinase, tyrosine kinase, serine/threonine kinase, crystal structure

1 **Kinase inhibitors: A burgeoning field**

2 The past one and half decades witnessed an unparalleled success in the development of
3 therapeutically useful kinase inhibitors, powered by tremendous progress in both academic and
4 industrial settings. The milestone approval of the first kinase inhibitor, imatinib, in 2001 by FDA,
5 was followed by a slow, yet steady approval of kinase inhibitors in the first ten years of this
6 century with almost one new approval per year on average. Concurrently, our understanding of
7 kinase signaling networks and disease pathology steadily grew, culminating in the approval of
8 fifteen new small molecule kinase inhibitors from January 2012 to February 2015 - an unparalleled
9 achievement in the history of pharmaceutical research. As of March 2015, a total of twenty-eight
10 small molecule kinase inhibitors have been approved along with a large number of other
11 compounds currently being evaluated in clinical and preclinical trials. In addition, more than one
12 million publications on kinases have been released, more than five thousand crystal structures of
13 kinases with or without small molecules have been solved, inhibition assays have been developed
14 for more than four-fifths of the human kinome, and small molecule kinase inhibitors have been
15 identified for about one-fifth of the human kinome. All these facts reflect the surging interest in
16 this field. Thus, it is now safe to state that the development of small molecule kinase inhibitors has
17 emerged as one of the most extensively pursued areas of drug discovery. In spite the abundance
18 of data, common binding modes and structural features of approved small molecule kinase
19 inhibitors are rarely reported in a systematic way that is easily accessible. Instead, information on
20 individual inhibitors and their analogues appears scattered and fragmented. In this review, we
21 provide a comprehensive overview and discuss the function mechanism and structural binding
22 features of approved small molecule kinase inhibitors based on co-crystal structures. With the
23 notion that fifteen kinase inhibitors were approved by FDA in the short period from 2012 to

1 February 2015, emphasis will be put on those small molecules, for which few SAR discussions have
2 been presented. The intention of this review is to compile structural and binding information
3 useful for the discovery of new kinase inhibitors, summarize current limitations and challenges,
4 and propose future directions in the field in light of the most successful design-to-approval
5 examples.

6 **Kinases**

7 Kinases catalyze the transfer of the γ -phosphate group of ATP onto a substrate, mediate most
8 signal transductions [1], and regulate various cellular activities, including proliferation, survival,
9 apoptosis, metabolism, transcription, differentiation, and a wide array of other cellular processes
10 [2]. Accumulating pharmacological and pathological evidence have revealed that kinases are
11 promising drug targets for the treatment of numerous diseases [3], such as cancers [4-6],
12 inflammatory diseases [7, 8], central nervous system (CNS) disorders [9], cardiovascular diseases
13 [10], and complications of diabetes [11].

14 Pioneering studies on the characterization of the phosphorylase kinase in the 1950s [12-14], and
15 the identification of the first kinase signaling cascade involving protein kinase A (PKA) in 1968 [15],
16 constituted the first few pieces of the jigsaw puzzle of kinase cascades. The “decade of protein
17 kinase cascades” in 1990s witnessed the unfolding of the mitogen-activated protein
18 kinases/extracellular signal-regulated kinases (MARK/ERK, also known as Ras-Raf-MEK-ERK)
19 pathway, the Janus kinases (JAK) pathway, and the phosphoinositide 3-kinase (PI3K) pathway [16,
20 17]. So far, 518 human kinases and more than 900 genes encoding proteins with kinase activity
21 have been confirmed [18, 19]. Albeit accounting for only about 5% of the total number of protein-

1 coding genes [20], kinases comprise one of the largest classes of proteins encoded by the human
2 genome.

3 **Kinase inhibitors**

4 Although diverse in primary amino acid sequence, the human kinases share a great degree of
5 similarity in their three-dimensional structures, especially in their catalytically active kinase
6 domain where the ATP binding pocket is located: a β -sheet containing N-terminal lobe (N-lobe), α -
7 helix dominated C-terminal lobe (C-lobe), and a connecting hinge region [21]. ATP binds in the
8 cleft formed between the N- and C-lobes and most kinase inhibitors perturb binding through
9 interactions with this region. A flexible activation loop starting with a conserved amino acid
10 sequence Asp-Phe-Gly (DFG) controls access to the active site [22] (Figure 1A). Categorized by
11 binding modes, kinase inhibitors can be grouped into two classes: irreversible and reversible
12 inhibitors. The former tend to covalently bind with a reactive nucleophilic cysteine residue
13 proximal to the ATP binding site, resulting in the blockage of the ATP site and irreversible
14 inhibition. The latter can be further classified into four main types based on the conformation of
15 binding pocket and the DFG motif [23, 24] (Figure 1B). Type I inhibitors are ATP competitive
16 inhibitors that bind to the active forms of kinases with the aspartate residue of the DFG motif
17 facing into the active site of the kinase. Type II inhibitors bind to the inactive forms of kinase with
18 the aspartate residue of the DFG motif protruding outwards from the ATP binding site of the
19 kinase. Many type II inhibitors exploit specific pockets accessible in a region adjacent to the ATP
20 binding site due to the rotation of the DFG motif. In the type III binding mode, inhibitors bind
21 exclusively in an allosteric pocket adjacent to ATP without making any interaction with the ATP
22 binding pocket. Type IV inhibitors bind to an allosteric site remote from the ATP binding pocket

1 [25]. Besides, some kinase inhibitors, such as bisubstrate and bivalent inhibitors (Type V) [26],
2 exhibit more than one of the above-mentioned binding modes.

3 Small molecule kinase inhibitors are useful reagents to investigate and elucidate kinase
4 functions in various cellular activities [5]. The dominant dogma that the kinase domain was too
5 conserved to enable the selective inhibition by small molecules was challenged in the late 1980s
6 when the first examples of selective kinase inhibitors against the epidermal growth factor receptor
7 (EGFR) were reported [27, 28]. Since then, a large number of kinase inhibitors of various structural
8 features and inhibition profiles have been identified aided by the deepening understanding of
9 structural biology [3], especially the kinase/inhibitor binding complex elucidated by high resolution
10 X-ray crystallography [29, 30].

11 Among the 28 clinically approved kinase inhibitors, most are tyrosine kinase inhibitors [31], few
12 are serine/threonine kinase inhibitors, and one, idelalisib, is a lipid kinase inhibitor that was
13 approved in Jul., 2014 (Figure 2). Judged by different binding modes, 26 are reversible inhibitors,
14 and the remaining two, afatinib and ibrutinib, are irreversible inhibitors. Despite several promising
15 allosteric kinase inhibitors being currently in clinical trials at different stages, trametinib is the only
16 type III inhibitor approved so far. In this review, approved small molecule kinase inhibitors are
17 discussed and grouped into different classes based on their binding modes and targets.

18 **Approved tyrosine kinase inhibitors**

19 *Reversible non-receptor tyrosine kinase (NRTK) inhibitors*

20 BCR-Abl was the first kinase for which a small molecule inhibitor was successfully approved [32].

21 On another note, being the first approved kinase inhibitor and a revolutionary success for the

1 treatment of chronic myeloid leukemia (CML) [17], imatinib has been the subject of various SAR
2 studies to guide the design of next-generation inhibitors and provide a deeper understanding of
3 the inhibition mechanism. Considerable efforts seek to develop inhibitors based on structural
4 features derived from imatinib and its binding mode with BCR-Abl [33, 34]. Five BCR-Abl inhibitors
5 have been approved so far: imatinib (Gleevec[®], Novartis), dasatinib (Sprycel[®], Bristol-Myers-
6 Squibbs), nilotinib (Tasigna[®], Novartis), Bosutinib (Bosulif[®], Wyeth), and Ponatinib (Iclusig[®], Ariad
7 Pharm.).

8 Imatinib, nilotinib, and ponatinib bind with inactive BCR-Abl with the DFG-motif adopting an
9 “out” conformation, utilizing three binding pockets (Figure 3). The pyridine-pyrimidine moiety of
10 imatinib forms a conserved hydrogen bond with hinge residue Met318. The tolyl group occupies a
11 hydrophobic pocket, and the amino group of the tolylaminopyrimidine moiety forms a hydrogen
12 bond with the gate-keeper residue Thr315. The terminal piperazinylphenyl group binds inside an
13 allosteric pocket, formed due to the flipped conformation of the DFG motif, where the piperazinyl
14 amine forms bidentate ionic interactions with His361 and Ile360. Besides, hydrogen bonds are
15 formed between the amide connecting link and Glu286, Asp 381 [35] (Figure 3A and 3B). In spite
16 of high efficacy and limited toxicity in comparison with traditional chemotherapy drugs, point
17 mutations in the kinases domain of BCR-Abl led to the development of drug resistance against
18 imatinib [36, 37]. Thus, nilotinib was developed as a second-line therapy for CML that is imatinib-
19 resistant due to point mutations on BCR-Abl, including E255V, M351T, and F486S. Nilotinib shares
20 the same pyridine-pyrimidine-aminotolyl moiety with imatinib, the difference being the long chain
21 binding within the allosteric pocket. The imidazole-phenyl moiety and the attached
22 trifluoromethyl group make it possible for nilotinib to bind deeper and tighter within the allosteric
23 pocket (Figure 3C and 3D). Nilotinib is potent against most mutations but not the common

1 gatekeeper mutation T315I which blocks the binding into the allosteric pocket due to mutation of
2 the small threonine residue to a bulky isoleucine residue. In this context, ponatinib was developed
3 as a new BCR-Abl inhibitor that exhibits potent T315I inhibitory activity. Instead of having a
4 pyrimidineamino linker interacting with the gatekeeper residue Thr315, a slim alkyne linker that
5 overcomes steric hindrance due to mutation of the gate-keeper residue was incorporated in
6 ponatinib. Besides, ponatinib bears the piperizinyphenyl group of imatinib and the trifluoromethyl
7 group of nilotinib, resulting in a more compact interaction with the allosteric pocket (Figure 3E and
8 3F).

9 Dasatinib and Bosutinib are the two approved inhibitors that bind with the active conformation
10 of BCR-Abl with the activation loop fully extended for substrate binding. As for dasatinib (Figure
11 4A), the nitrogen of the thiazole core and the attached amino group form hydrogen bonds with
12 hinge residue Met318. The long hydroxyethylpiperazinyl tail is exposed to the solvent region. The
13 terminal toluidine group points towards a hydrophobic pocket close to the gatekeeper residue
14 Thr315, which interacts with the connecting amide link through a hydrogen bond (Figure 4B and
15 4C). Thus, T315I mutation related drug resistance also occurs in patients treated with dasatinib. In
16 contrast to the other four approved BCR-Abl molecules, bosutinib bears an anilinequinoline core
17 that is similar to the anilinequinazoline core of some EGFR inhibitors (Figure 4D). A hinge hydrogen
18 bond is formed between the quinoline nitrogen and the backbone amide of Met 318. The
19 substituted aniline group occupies the hydrophobic pocket adjacent to Thr315. The nitrile group
20 extends into another Thr315-adjacent pocket, which may host water molecules to form conserved
21 water-mediated hydrogen bond interactions with small molecule inhibitors to contribute to kinase
22 selectivity [38]. Due to the propensity of BCR-Abl to adopt a certain conformation at low pH values
23 needed for crystallization, the DFG-motif of the bosutinib-Abl complex exhibits a different

1 conformation from that of dasatinib-Abl complex (Figure 4E and 4F). While a bosutinib-Src
2 complex with the DFG-motif adopts the same conformation as shown in the dasatinib-Abl complex
3 has been reported recently [38].

4 Janus kinases (JAKs) are a family of intracellular NRTKs that are required for multiple signaling
5 pathways initiated by cytokines and growth factor receptors to phosphorylate Signal Transducers
6 and Activators of Transcription (STAT) proteins [39, 40]. Four isomers, JAK1, JAK2, JAK3 and
7 Tyrosine kinase 2 (TYK2) have been identified as JAK family kinases. JAK3 is exclusively expressed
8 in cells of the lymphoid lineage and plays important roles in the immune system [41], while the
9 other three isoforms are ubiquitously expressed and regulate a range of physiological functions
10 [42]. Although small molecule kinase inhibitors against JAKs are potential agents for the treatment
11 of autoimmune and neoplastic disorders [43], the development of isoform-selective JAK inhibitor
12 is challenging due to the high sequence similarity among the four JAK kinases [7].

13 Ruxolitinib (Jakafi[®], Incyte Corp.) was the first approved JAK inhibitor (Figure 5A). It inhibits both
14 JAK1 and JAK2 and is used for the treatment of myeloproliferative disorders, such as myelofibrosis.
15 Tofacitinib (Xeljanz[®], Pfizer) was approved by FDA as a JAK3 selective inhibitor in 2012 for the
16 treatment of rheumatoid arthritis (Figure 5B). However, the efficacy of tofacitinib has been
17 hindered by side effects, such as anemia and neutropenia, probably due to undesirable pan-JAK
18 inhibition, thus it was not approved by European regulatory agencies. Both molecules bear a
19 pyrrolo[2,3-*d*]pyrimidine scaffold, and whereas no co-crystal structure of ruxolitinib with JAK
20 kinase has been published yet, crystal complexes of tofacitinib with JAK1, JAK2, and JAK3 are
21 readily available [44, 45]. Tofacitinib binds within the ATP pocket of JAKs. The pyrrolo[2,3-*d*]
22 pyrimidine scaffold forms two hydrogen bonds with hinge residues Leu905 and Glu903 in JAK3

1 (Leu932 and Glu930 in JAK2). The terminal cyanoacetyl handle extends into a cleft underneath the
2 P-loop in the N-lobe. The methyl group of the piperidine ring occupies a small hydrophobic pocket
3 in the C-lobe (Figure 5C and 5D). Compounds with better selectivity towards JAK3 and reduced
4 side effects are currently being investigated as the next generation JAK inhibitors [46, 47].

5 *Reversible receptor tyrosine kinase (RTK) inhibitors*

6 ErbB, named for their homology to the erythroblastoma viral gene product *v-ErbB*, is a family of
7 RTKs that includes four members, ErbB1/epidermal growth factor receptor (EGFR), ErbB2/human
8 epidermal growth factor receptor 2 (Her2), ErbB3/Her3, and ErbB4/Her4 [48]. The ErbB cascade is
9 one of the most extensively studied signaling transduction pathways [49, 50], and the ErbB
10 inhibitors gefitinib (Iressa[®], AstraZeneca), erlotinib (Tarceva[®], OSI Pharm.), lapatinib (Tykerb[®],
11 GlaxoSmithKline), vandetanib (Caprelsa[®], AstraZeneca), and afatinib (Gilotrif[®], Boehringer
12 Ingelheim) constitute one of the largest groups of approved small molecule kinase inhibitors. All
13 five inhibitors bear a common quinazoline scaffold occupying the ATP adenine binding pocket, a 4-
14 amino substituent binding in a hydrophobic pocket close to the kinase hinge, and a long chain in
15 the 6- and/or 7-position extending towards solvent to increase the overall solubility of the
16 molecule. In contrast to the other four reversible inhibitors, afatinib bears an enone moiety in the
17 long solubilizing chain, enabling it to form a covalent bond. Thus, afatinib will be discussed
18 together with ibrutinib in the section for covalent inhibitors.

19 A complex of wild type EGFR with gefitinib was first reported in 2007 [51] (Figure 6A and 6B).
20 Structures of EGFR kinases with mutations at L858R or T790M have also been solved by several
21 different groups. Extensive efforts to crystallize drug-resistant double mutant L858R+T790M EGFR
22 failed to give diffraction-quality crystals, until a structure of EGFR with L858R+T790M+V948R

1 mutations was recently co-crystalized with gefitinib [52] (Figure 6C). In contrast to the wild type
2 EGFR conformation that showed an active state with Leu858 buried in the kinase N-lobe, this
3 mutant EGFR structure adopted an inactive-like state where Arg858 residue is exposed to the
4 solvent front. Although gefitinib, erlotinib and vandetanib are the few inhibitors for which no
5 experimental evidence regarding inactive state recognition has been collected so far, this gefitinib-
6 mutant EGFR co-crystal structure showed that maybe there is no structural hindrance for these
7 inhibitors to bind with the inactive form of EGFR. SAR and structural features obtained from these
8 mutant kinase complexes provide a new dimension for the development of kinase inhibitors that
9 may better address challenging issues regarding selectivity and drug-resistance. Due to the high
10 structural similarity, the erlotinib-EGFR complex showed the same binding mode with that of
11 gefitinib-EGFR complex, albeit with different 6,7-quinazoline substituents exposed in the solvent
12 region [53] (Figure 6D-6F).

13 Lapatinib is a dual EGFR and ErbB2 inhibitor. In contrast to the type I binding mode as shown for
14 erlotinib and gefitinib, lapatinib binds with the inactive conformation of EGFR, utilizing not only
15 the adenine pocket and the specific hydrophobic pocket, but also an allosteric pocket formed due
16 to the conformation change of the DFG-motif [54] (Figure 6G, 6H). Equivalent to its binding with
17 EGFR, lapatinib binds with the inactive conformation of ErbB4, which shares the same lapatinib-
18 contacting residues with ErbB2 [55] (Figure 6I). Although it has been assumed that allosteric
19 modulators like type II inhibitors may achieve higher selectivity in comparison with type I
20 inhibitors due to the utilization of an allosteric pocket unfolded through the conformational
21 change[56], some of the currently available allosteric inhibitors are highly nonselective and a
22 recent binding mode analysis suggested that type II inhibitors do not show an intrinsic selectivity
23 advantage over type I inhibitors [57].

1 Vandetanib is a multiple kinase inhibitor against EGFR, vascular endothelial growth factor
2 (VEGFR), and RET [58]. Despite the absence of a vandetanib-EGFR complex, a co-crystal structure
3 of vandetanib with RET of class XIV RTK showed the same type I binding as seen in gefitinib and
4 erlotinib [58](Figure 6J-6L).

5 VEGFRs, comprised of three major isoforms, 1, 2, and 3, are receptors of vascular endothelial
6 growth factor (VEGF) that is an important signaling protein in vasculogenesis and angiogenesis [59,
7 60]. Like Bcr-Abl and EGFR, VEGFR is among the earliest and most extensively-studied kinases
8 targeted by synthetic small molecules for cancer treatment. Seven approved small molecule
9 inhibitors target VEGFR as their primary target: sorafenib (Nexavar[®], Bayer), sunitinib (Sutent[®],
10 Pfizer), pazopanib (Votrient[®], GlaxoSmithKline), axitinib (Inlyta[®], Pfizer), regorafenib (Stivarga[®],
11 Bayer), nintedanib (Ofev[®],Boehringer Ingelheim), and lenvatinib (Lenvima[®], Eisai Inc.).

12 The binding mode of VEGFR with small molecule inhibitors has been the subjects of SAR
13 discussions in many studies due to the early resolution of corresponding co-crystal structures.
14 General binding mode and common structural features are shown based on the VEGFR2-
15 complexes that are available for four of the seven approved VEGFR inhibitors [61] (Figure 7A-7H):
16 the conserved hinge bond is formed between the picolinamide group of sorafenib with Cys919,
17 the indolinone core of sunitinib with Glu917 and Cys919, the indazole core of axitinib with Glu917
18 and Cys919, and the indolinone core of nintedanib with Glu917 and Cys919. Except for sunitinib,
19 the allosteric pocket formed due to the relocation of the DFG group is utilized by the remaining
20 three molecules: the terminal 4-chloro-3-(trifluoromethyl)phenyl group of sorafenib binds in a
21 deep hydrophobic allosteric pocket and the urea group lying in an allosteric channel forms
22 hydrogen bonds with N-lobe residue Glu885 and the activation loop residue Asp 1046, axitinib

1 interacts with a small part of the allosteric pocket through its terminal benzamide group, and
2 nintedanib binds with the allosteric pocket using its terminal methylcarboxy group. Another
3 difference among these four compounds is the presence of a solubilizing chain: both sunitinib and
4 nintedanib have a long terminal chain lying in the solvent region, axitinib's moderate-length
5 pyridylvinyl chain extends to the solvent front, while sorafenib is basically buried inside the
6 binding pocket without direct interaction with the solvent. In the case of nintedanib, ionic
7 interactions are formed between the N-methylpiperazinyl group and Glu850. Regorafenib only
8 differs from sorafenib by the presence of a fluorine atom (Figure 7I), thus similar type II binding
9 with VEGFR2 as for sorafenib is expected. Both sorafenib and regorafenib are multi-target protein
10 kinase inhibitors. Besides inhibition of VEGFR and B-raf, sorafenib has also been shown to be a
11 potent low nanomolar inhibitor of p38 α through binding with its inactive conformation (3GCS, 2.1
12 Å) [62]. A predicted type II binding mode of pazopanib with VEGFR2 is depicted (Figure 7J) based
13 on a VEGFR2-complex with a similar indazolylpyrimidine-2,4-diamine compound that only differs
14 in the aniline substituent at the 2-position of the pyrimidine-2,4-diamine [63]. Although a co-
15 crystal structure of VEGFR2 with lenvatinib (PDB ID: 3WZD) has been reported in November 2014
16 [64], for unspecified reasons, it is still not accessible through the PDB database. It was reported
17 that lenvatinib binds into both the ATP binding site and a neighboring allosteric region of VEGFR2
18 with the DFG motif adopting an "in" conformation (Figure 7K), making it an inhibitor that
19 possesses both type I and II binding features [64].

20 Anaplastic lymphoma kinase (ALK) is a RTK that shares great sequence similarity to leukocyte
21 tyrosine kinase (LTK) [65]. Chromosomal rearrangements in ALK have been detected in different
22 types of human cancer, and together with other oncogenic evidence, ALK has been adopted as

1 another attractive target for cancer treatment with more than 10 molecules currently undergoing
2 clinical trials [66].

3 Crizotinib (Xalkori[®], Pfizer) was the first ALK inhibitor approved (Figure 8A), for the treatment of
4 late stage lung cancer, anaplastic large cell lymphoma, and neuroblastoma. It was also the first
5 drug specifically targeting NSCLC patients. Besides ALK, crizotinib also acts on ROS proto-oncogene
6 1 encoded kinase (ROS1) of the tyrosine kinase insulin receptor class and MET proto-oncogene
7 encoded kinase (MET) of the hepatocyte growth factor receptor (HGFR) class[67, 68]. A co-crystal
8 structure with ALK showed that crizotinib binds with the ATP-binding pocket in a type I mode. The
9 aminopyridine core sits at the adenine pocket and makes hydrogen bonds with hinge residues
10 Glu1197 and Met1199. The methyl group of the benzyloxy moiety binds with a small hydrophobic
11 pocket under the N-lobe. The 2,6-dichloro substituent of the terminal benzyl handle contributes to
12 the high potency against c-MET. Overall, crizotinib does not fully utilize the structural features of
13 the ATP binding pocket of ALK, which partially explained its poor selectivity [68] (Figure 8B, 8C).

14 Ceritinib (Zykadia[®], Novartis) was developed as a second-generation ALK inhibitor for the
15 treatment of non-small-cell lung carcinoma (NSCLC) with developed resistance to crizotinib due to
16 rearrangements of the ALK gene[69] (Figure 8D). It has been shown that ceritinib potently
17 overcomes ALK bearing L1196M, G1269A, I1171T, and S120Y mutations, but not ALK with G1202R
18 and F1174C mutations [70]. ALK-ceritinib co-crystal structure showed a similar binding mode to
19 that of ALK-crizotinib complex with the DFG motif adopting the “in” conformation [70]. The
20 conserved hydrogen bonds were formed between the 2,4-diaminopyrimidine core and hinge
21 residue Met1199. The isopropylsulfonylphenyl handle binds deeper inside the hydrophobic pocket,

1 and the anchor-shaped terminal 2-isopropoxy-3-(piperidin-4-yl)phenyl group lies in the interface
2 between solvent and the ATP binding pocket.

3 MET, or c-MET, is a tyrosine kinase that is the only known receptor of HGF [71, 72]. MET induced
4 activation of signaling cascade recruits downstream effectors including SRC, PI3K, tyrosine
5 phosphatase SRC homology 2 domain-containing phosphatase 2 (SHP2), transcription factor signal
6 transducer, and activator of transcription (STAT-3), regulating proliferation, motility, migration,
7 and a wide range of other cellular activities [73]. Given its pivotal role in cancer development and
8 progression, MET has been promoted as a versatile candidate for cancer treatment [74]. Besides a
9 small group of selective MET inhibitors, most current MET inhibitors target multiple kinases,
10 including the two approved molecules: above-mentioned crizotinib and the dual MET and VEGFR2
11 inhibitor cabozantinib (Cometriq®, Exelixis). A recent study showed that cabozantinib overcomes
12 crizotinib resistance stemming from acquired mutations in ROS1 [75].

13 MET-crizotinib complex showed a type I binding mode similar to that of the ALK-crizotinib
14 complex with the DFG adopting an “in” conformation [68] (Figure 9A). The hinge hydrogen bonds
15 involving the aminopyridine core are preserved, while the 3-fluoro-2,6-dichlorobenzyl moiety
16 binds in a big hydrophilic pocket adjacent to the solvent front (Figure 9B, 9C). In spite of the
17 absence of a MET co-crystal structure with cabozantinib (Figure 9D), the MET complex with
18 compound DWF (Figure 9E), a closely related analogue, showed a potent type II binding mode. The
19 aminopyrimidine core and the connecting fluorophenyl group lie in the adenine pocket and
20 hydrophobic pocket utilized by crizotinib, respectively. The DFG-out conformation opens a
21 hydrophobic allosteric pocket that is occupied by the terminal 4-fluorophenyl group. Besides
22 forming a hydrogen bond with the N-lobe residue Lys1110, the cyclopropane-dicarboxamide link

1 binds with an allosteric channel interacting directly with the DFG residue Asp1222 through the
2 formation of a hydrogen bond. The sulfonylphenyl group extends to the solvent and forms
3 hydrogen bonds with C-lobe residues Asp1164 and Asn1167 (Figure 9F, 9G).

4 **Approved irreversible protein kinase inhibitors**

5 The EGFR inhibitor afatinib was the first clinically approved irreversible kinase inhibitor, followed
6 shortly by ibrutinib in November 2013. The approval of these two molecules validates the strategy
7 of incorporating Michael acceptor functionality in small molecule inhibitors to form a covalent
8 bond with a cysteine residue in the active site of kinases. This type of irreversible inhibitors is
9 expected to achieve greater specificity and potency, although concerns have been raised regarding
10 potential toxicities.

11 Co-crystal structures of both wild type EGFR-afatinib and mutant T790M EGFR-afatinib showed
12 a type I binding mode that is in high degree of similarity with other approved reversible EGFR
13 inhibitors sharing the same anilinoquinazoline core (Figure 10A). A conserved hydrogen bond is
14 formed between hinge residue Met793 and the quinazoline ring. Electron density indicated that
15 formation of a covalent C-S bond (1.8 Å) between the enone tail and Cys797 at the edge of the
16 active site in the C-lobe [76] (Figure 10B, 10C).

17 Ibrutinib (Imbruvica®, Pharmacyclics Inc.) is a non-receptor tyrosine kinase inhibitor that targets
18 Bruton's tyrosine kinase (BTK), which is an essential component of B-cell receptor signaling in
19 regulating survival and proliferation of chronic lymphocytic leukemia (CLL) cells [77]. It was
20 approved for the treatment of mantle cell lymphoma in November 2013, and then for CLL in
21 February 2014 [78]. Global sales of Ibrutinib are expected to reach 9 billion US dollars in 2020 [79].
22 A co-crystal structure of BTK with ibrutinib has yet to be reported, but one of BTK with a close

1 analogue of ibrutinib, B43, could be used to deduce a general binding mode between BTK and
2 ibrutinib [80] (Figure 10D, 10E). B43 binds to the ATP site with the activation loop displaying a
3 “DFG-in” conformation. The 4-amino pyrrolopyrimidine of B43 mimics the adenine ring of ATP,
4 making several hydrogen bond interactions with the hinge region. The terminal phenyl group is
5 twisted out of the connecting phenyl ether plane to enter a hydrophobic pocket mainly formed by
6 the N-lobe residues. The phenoxyphenyl group forms π -stacking interactions with residues of this
7 hydrophobic pocket. The cyclopentyl group of B43 extends towards Cys481 of the activation loop
8 (Figure 10F). In the case of ibrutinib, the cyclopentyl group is replaced with an *N*-acryloylpiperidine
9 group that acts as a Michael acceptor in reaction with the vicinal cysteine.

10 **Approved serine/threonine kinase inhibitors**

11 Serine/threonine kinase B-Raf, one of the three isoforms of the Raf family, has been established as
12 an attractive anticancer target [81]. Replacement of Val600 with Glu600 within the activation loop
13 of the kinase domain accounts for 90% of B-Raf mutations [82], resulting in destabilization of the
14 inactive conformation, elevated activation of the MAPK pathway, and enhanced promotion of cell
15 survival and proliferation. Efforts in developing small molecule kinase inhibitors lend to the
16 approved of the first B-Raf inhibitor Vemurafenib (Zelboraf[®], Roche) in 2011 for the treatment of
17 metastatic melanoma and thyroid tumors [81], followed by the approved of Dabrafenib (Tafinlar[®],
18 GlaxoSmithKline) in 2013. Besides, the tyrosine kinase inhibitor sorafenib has also been shown to
19 inhibit Raf kinases including C-Raf and B-Raf [82].

20 Vemurafenib (Figure 11A) was developed using a fragment-based drug discovery strategy. The
21 V600E B-Raf-vemurafenib co-crystal structure showed a type I binding mode. Vemurafenib
22 occupies the ATP binding site with a DFG-in conformation, enabling the formation of hydrogen

1 bond interactions between the sulfonamide moiety and the DFG residues. Hydrogen bonds are
2 also formed between the pyrrolopyridine core and hinge residue Cys532 and Gln530, mimicking
3 that of the adenine core of ATP. The terminal 4-chlorophenyl group is exposed to the solvent front.
4 Besides, an outward shift of the regulatory α C-helix caused by vemurafenib binding to the kinase
5 was observed [83] (Figure 11B, 11C). Although no co-crystal structure of dabrafenib (Figure 11D)
6 with B-Raf has been obtained yet, a complex of mutant V600E B-Raf with compound **20** (Figure
7 11E), a diarylthiazole derivate of dabrafenib, showed an interacting mode that shares features of
8 type I binding. Compound **20** binds the ATP site with the activation loop adopting a DFG-in
9 conformation. Hydrogen bond interactions with the hinge and the DFG residues were preserved
10 through the acetamidopyridine handle and the sulfonamide moiety, respectively. The 2,5-
11 difluorophenyl moiety extends inside a hydrophobic pocket, or Ras-selective pocket, which is
12 formed through the outward movement of the α C-helix. The thiazole core occupies the ribose
13 pocket that is barely utilized by other kinase inhibitors, and the cyclopropylpiperidine tail attached
14 to the thiazole core extends towards the solvent environment [84] (Figure 11F). A mechanistic
15 study indicated that the activation loop of B-Raf is held in an inactive state by association with the
16 P-loop. Mutations of the activation loop or the P-loop disrupt the inactive conformation and
17 convert B-Raf into its active conformation. Co-crystal structure of tyrosine kinase inhibitor
18 sorafenib with both wild type and mutant B-Raf showed different binding modes when the Val599
19 of the activation loop is mutated to Glu599 [82] (Figure 11G-11I).

20 Along the MAPK pathway, MEK is another target for which a considerable number of small
21 molecule inhibitors have been identified [85], including the only approved molecule trametinib
22 (Mekinist[®], GlaxoSmithKline) (Figure 12A). Trametinib was developed based on a high-throughput
23 screening hit that bears the same pyridopyrimidinetrione core. SAR studies driven by growth

1 inhibitory activity against cancer cell lines lead to the discovery of trametinib [86], whose target
2 was then confirmed as MEK1 and MEK2 guided by the structural features of known MEK inhibitors.
3 The co-crystal structure of MEK1 with an analogue of trametinib, TAK-733 (Figure 12B), showed a
4 type III binding mode. The pyridopyrimidinedione core lies in an allosteric pocket adjacent to the
5 ATP binding pocket with the pyridine oxygen forming hydrogen bonds with Val211 and Ser212 and
6 the pyrimidine oxygen interacting with Lys97. The 2-fluoro-4-iodoaniline moiety functions as a
7 recognition motif for the hydrophobic pocket of the MEK allosteric site. The hydroxyl groups of the
8 terminal dihydroxypropyl chain forms hydrogen bonds with both the ATP phosphate and Lys97 [87]
9 (Figure 12C). A combination strategy of B-Raf inhibitor dabrafenib with MEK inhibitor trametinib,
10 approved for the treatment of mutant V600E/K metastatic melanoma by FDA in early 2014, has
11 been used to overcome drug resistance that occurs within about half a year after applying B-Raf
12 inhibitors [88, 89].

13 Serine/threonine kinases Akt and mTOR of the PI3K/Akt/mTOR pathway are also promising
14 targets [90]. Although no small molecule kinase inhibitors has been approved for either Akt or
15 mTOR, a pipeline of candidates are currently undergoing various clinical trials in different phases
16 [91]. For mTOR inhibitors, three natural-product-based macrolides, sirolimus, temsirolimus, and
17 everolimus, were approved for clinical use in 1999, 2007, and 2009, respectively [90].

18 Cyclin-dependent kinases (CDKs) represent another group of serine/threonine kinases that have
19 been studied as targets for therapeutic intervention in various types of cancers and other
20 proliferative diseases [92]. Intensive efforts have been made in the past two decades to discover
21 inhibitors with varied selectivity against the eleven isoforms of CDKs, resulting in the emergence of
22 approximately twenty CDK inhibitors currently in various clinical trials [93]. Eventually, the first

1 CDK inhibitor palbociclib (Ibrance®, Pfizer) was approved in February 2015 inhibitor for the
2 treatment of breast cancer.

3 Palbociclib is a selective CDK4 and CDK6 inhibitor (Figure 13A). Due to conformational difference
4 in the hinge region of CDKs, the selectivity profiles of CDK inhibitors are closely connected with
5 their binding orientations [94]. Co-crystal structure of palbociclib with CDK6 showed a tight
6 binding mode, in which hydrogen bonds are formed between the hinge residue Val101 and the
7 aminopyrimidine moiety and between the DFG residue Asp163 and the 6-acetyl group. The 5-
8 methyl and 6-acetyl groups fully occupy a hydrophobic pocket in the back of the ATP binding site.
9 The piperazinyipyridinylamino substituent at the 2-position of the pyrido[2,3-*d*]pyrimidinone core
10 binds into a specificity pocket facing to the solvent front (Figure 13B, 13C). Overall, palbociclib
11 binds tightly into CDK6 and adopts a comparatively rigid orientation in comparison with other pan-
12 CDK inhibitor due to the above-mentioned binding features [94].

13 **Approved lipid kinase inhibitor**

14 Lipid kinases, such as phosphoinositide 3 kinases (PI3Ks), were discovered as early as the 1980s
15 [95]. It has been convincingly established that activation and mutation of PI3Ks and other key
16 components of this signaling pathway play key roles in various stages of tumor development [96].
17 Considerable efforts from both academia and industry have been involved in the development of
18 small molecule lipid kinases since 1980s, but the clinical success of these inhibitors has been
19 minimal until the approval of the first lipid kinase inhibitor, idelalisib (Zydelig®, Gilead Sciences),
20 for CLL in combination with monoclonal antibody rituximab in July 2014 [97]. The approval of
21 idelalisib, together with the BTK inhibitor ibrutinib, provides encouraging transformation in the
22 treatment of CLL [98].

1 Idelalisib is a PI3K δ inhibitor [99] (Figure 14A). The crystal complex of PI3K δ with idelalisib
2 revealed a type II binding that is similar to that of another selective PI3K δ inhibitor PIK39 [100].
3 Idelalisib adopts a propeller-shaped conformation with the DFG motif posing in an “out”
4 conformation [101]. The 5-fluoroquinazolinone moiety squeezes into an induced hydrophobic
5 specificity pocket. The ethyl group binds in a hydrophobic pocket and the phenyl group extends
6 into a hydrophobic region that is close to the solvent front. The hinge hydrogen bond, which is a
7 highly conserved feature for PI3K inhibition [102], is formed between Val828 and the purine
8 moiety that occupies the adenine pocket [101] (Figure 14B, 14C). Except for being approved for
9 CLL, idelalisib has also been granted accelerated approval for relapsed follicular B-cell non-Hodgkin
10 lymphoma and relapsed small lymphocytic lymphoma [103, 104].

11 More than twenty other PI3K inhibitors, including single-isoform inhibitors, such as PI3K α
12 inhibitor buparlisib (phase III, Novartis), selective-isoform inhibitors, dual inhibitors of PI3K and
13 mTOR, and pan class-I PI3K inhibitors, are in development for cancers and inflammatory diseases
14 [102]. However, the clinical data accumulated so far suggest that PI3K inhibitors have limited
15 single-agent activity [105], possibly due to negative feedback inhibition and the resulting
16 reactivation of downstream receptor signaling [106, 107]. Thus, rational combination strategies
17 using monoclonal antibodies, tyrosine kinase inhibitors, and serine/threonine kinase inhibitors are
18 needed to assist the clinical usage of PI3K inhibitors.

19 **Limitations and challenges**

20 Kinase-based drug discovery has achieved dramatic progress in the past fifteen years. Although
21 kinase inhibition stands for a young therapeutic strategy in comparison with other traditional
22 tactics targeting G-protein-coupled receptors (GPCRs), membrane channels and transporters,

1 protease, etc., an analysis of FDA-approved cancer drugs since 1980s reveals that kinases have
2 already taken over from G-protein-coupled receptor (GPCR) as the most sought-after cellular
3 targets for cancer treatment [108]. Our analysis of all FDA-approved molecule kinase inhibitors
4 with a focus on binding mechanism and structural features reveals some general conclusions that
5 form the current landscape of developing kinase inhibitors and reflects a number of significant
6 challenges in spite of achieved advances.

7 First, only a small subset of the human kinome has been studied. Most kinase inhibition efforts
8 are limited to a select group of kinases that belong to the tyrosine kinase (TK) group, although
9 promising results are emerging for inhibition of kinases in groups of tyrosine-kinase like (TKL),
10 containing CDK, MAPK, GSK3 and CLK kinases (CMGC), containing PKA, PKG and PKC kinases (AGC),
11 and containing the calcium/calmodulin-dependent protein kinases (CAMK) in recent years. This
12 imbalance is clearly illustrated by the fact that inhibitors of three groups of tyrosine kinases, BCR-
13 Abl, ErbBs, VEGFRs, account for eighteen of the twenty-seven approved protein kinase inhibitors.

14 Second, in contrast with protein kinase inhibitors, only one lipid kinase inhibitor is currently on
15 the market. Even though lipid kinase inhibitors were reported as early as 1990s and a variety of
16 clinical and pre-clinical lipid kinase inhibitors have been published [102], few have showed
17 sufficient activity used in single-agent trials.

18 Third, despite the fact that kinases signaling cascade regulates diverse cellular activities related
19 to inflammatory indications, CNS disorders, cardiovascular disease, diabetes, and others, in
20 addition to cancer, most currently available inhibitors, including 26 out of the 28 approved kinase
21 inhibitors, are developed mainly for cancer treatment.

22 Fourth, many of the current kinase inhibitors were designed based on previously approved
23 compounds, as shown by the high structural similarity among approved ErbB inhibitors, e.g., five

1 ErbB inhibitors share the same 4-(arylamino)quinazoline core with different 6- and/or 7-
2 substituents. Consequently, only a small subset of chemotypes are being investigated, which is
3 clearly reflected by the limited number of moieties that are being incorporated in the approved
4 molecules.

5 Fifth, most inhibitors function as reversible inhibitors binding in the ATP binding pocket and due
6 to the high sequence similarity around the ATP binding pockets of kinases, it has been a daunting
7 task to develop kinase inhibitors with potent inhibition against desirable targets and minimal
8 interactions with off-targets.

9 Sixth, closely connected with the previous point, a large number of inhibitors interact with more
10 than one target. In contrast, few absolute-selective inhibitors, which might be evaluated as dual or
11 multiple target inhibitors if a more comprehensive screening assay was used [109], have been
12 identified so far.

13 **Future directions**

14 Based on the current trends discussed above, some challenging questions that might serve as
15 directions for future development of small molecule kinase inhibitors and push the boundary of
16 the research in this field need to be addressed appropriately.

17 First, the fact that current kinase inhibitors focus only on a small subset of the human kinome
18 indicates that many kinases are neglected. Thus, there is a need to develop tools and selective
19 probes to uncover the functions of these unknown kinases [110], which might serve as new
20 targets for small molecule inhibitors. It is encouraging to see the approval of a first inhibitor
21 targeting certain kinases in the past three years, like trametinib as the first approved MEK inhibitor
22 in 2013, ibrutinib as the first approved BTK inhibitor in 2013, and palbociclib as the first approved
23 CDK inhibitor in 2015.

1 Second, although significant efforts have been devoted to the development of lipid kinase
2 inhibitors, the progress achieved is not as obvious as for protein kinase inhibitors. The approval of
3 the first and only lipid kinase inhibitor idelalisib in 2014 added support to the strategy of using
4 lipid kinase inhibitors as anticancer agents, especially in combination with other cancer treatment
5 agents and methods. Considering the pivotal roles of lipids kinases, such as PI3Ks, in cellular
6 cascade, it is reasonable to expect research on small molecule lipid kinase inhibitors for indications
7 including not only cancer but also inflammation, to be a promising direction in this field.

8 Third, except being utilized in the prevalent theme for cancer treatment, kinase inhibitors have
9 great potential in the treatment of nonlethal chronic diseases, such as cardiovascular and CNS
10 disorders. The successful approval of tofacitinib established the concept for the treatment of
11 arthritis. Even for cancer treatment, more knowledge needs to be gained to further understand
12 the multifaceted cancer biology.

13 Fourth, more pharmacophores need to be explored to diversify the scaffolds of kinase inhibitors.
14 Most currently approved kinase inhibitors are discovered based on hits from high-throughput
15 screening (HTS), while HTS is becoming increasingly less effective since most useful scaffolds have
16 already been retrieved from available compound libraries. So there is an urgent need to diversify
17 the molecules in compound library for screening. Natural products, which usually contain
18 pharmacophores and scaffolds that are different from most synthetic kinase inhibitors, could be a
19 useful source to inspire the construction of libraries with expanded structural diversity.

20 Fifth, despite the fact that most approved kinase inhibitors are type I and II reversible inhibitors,
21 the success of afatinib and ibrutinib stand as strong stimulators to rekindle the idea of targeting
22 kinases with irreversible inhibitors. On the other hand, type III and IV inhibitors might show

1 different efficacy and selectivity in comparison with type I and II inhibitors. In a word, novel
2 mechanism of action needs to be explored.

3 Sixth, the selectivity issue of kinase inhibitors has always been a controversial area. Early
4 promiscuous inhibitors, e.g. staurosporine, and later pan-selective inhibitors have functioned as
5 useful tools in oncology. Highly selective kinase inhibitors were actively sought after until the
6 recent theory that inhibitors with favorable selectivity or multi-target selectivity might be more
7 suitable for cancer treatment becoming more and more widely accepted. It has become clear that
8 kinase inhibitors do not have to be absolute-selective, a favorable selectivity profile is needed to
9 balance efficacy and toxicity.

10 **Concluding remarks**

11 Groundbreaking understanding of cellular signaling cascades at the molecular level has led to
12 major advances in kinase research over the past decades. The dramatic progress in applying the
13 strategy of targeted kinase inhibition in the past fifteen years has been highlighted by the
14 successful approval of no less than twenty-eight small molecule kinase inhibitors. An analysis
15 based on co-crystal structures of all approved inhibitors with a focus on binding mechanism and
16 structural features is presented herein to provide an updated overview of the achievements and
17 shape current limitations and challenges in this rapidly evolving field. Future directions that may
18 lead to the discovery of small molecule kinase inhibitors with novel function mechanisms, new
19 therapeutic indications, distinct structures, and different selectivity and pharmacological profiles
20 are also proposed. Although the current task of developing small molecule kinase inhibitors is
21 highly interdisciplinary, the ultimate answer to the question of which type of kinase inhibitor is
22 most useful will have to come from the accumulated clinical data of the approved molecules
23 discussed in this review.

1 **Acknowledgement**

2 The Lundbeck Foundation (R140-2013-13835) is gratefully acknowledged for financial support. We
3 thank Prof. David A. Tanner for proofreading of the manuscript.

4 **Supplementary data**

5 A poster with the generic name, commercial name, company, kinase target(s), chemical structure,
6 first approval date, and clinical indication(s) of the twenty-eight FDA approved small molecule
7 kinase inhibitors.

8

9 **References**

- 10 1 Johnson, L.N. and Lewis, R.J. (2001) Structural basis for control by phosphorylation. *Chem. Rev.*
11 101, 2209-2242
- 12 2 Adams, J.A. (2001) Kinetic and catalytic mechanisms of protein kinases. *Chem. Rev.* 101, 2271-
13 2290
- 14 3 Rask-Andersen, M., *et al.* (2014) Advances in kinase targeting: current clinical use and clinical
15 trials. *Trends Pharmacol. Sci.* 35, 604-620
- 16 4 Huang, M., *et al.* (2014) Molecularly targeted cancer therapy: some lessons from the past
17 decade. *Trends Pharmacol. Sci.* 35, 41-50
- 18 5 Ma, W.W. and Adjei, A.A. (2009) Novel agents on the horizon for cancer therapy. *CA Cancer J.*
19 *Clin.* 59, 111-137
- 20 6 Sun, C. and Bernards, R. (2014) Feedback and redundancy in receptor tyrosine kinase signaling:
21 relevance to cancer therapies. *Trends Biochem. Sci.* 39, 465-474

1 7 Clark, J.D., *et al.* (2014) Discovery and development of Janus Kinase (JAK) inhibitors for
2 inflammatory diseases. *J. Med. Chem.* 57, 5023-5038

3 8 Barnes, P.J. (2013) New anti-inflammatory targets for chronic obstructive pulmonary disease.
4 *Nat. Rev. Drug Discov.* 12, 543-559

5 9 Muth, F., *et al.* (2015) Tetra-substituted pyridinylimidazoles as dual inhibitors of p38 α mitogen-
6 activated protein kinase and c-Jun N-terminal kinase 3 for potential treatment of
7 neurodegenerative diseases. *J. Med. Chem.* 58, 443-456

8 10 Kikuchi, R., *et al.* (2014) An antiangiogenic isoform of VEGF-A contributes to impaired
9 vascularization in peripheral artery disease. *Nat. Med.* 20, 1464-1471

10 11 Banks, A.S., *et al.* (2015) An ERK/Cdk5 axis controls the diabetogenic actions of PPAR γ .
11 *Nature* 517, 391-395

12 12 Burnett, G. and Kennedy, E.P. (1954) The enzymatic phosphorylation of proteins. *J. Biol. Chem.*
13 211, 969-980

14 13 Fischer, E.H. and Krebs, E.G. (1955) Conversion of phosphorylase b to phosphorylase a in muscle
15 extracts. *J. Biol. Chem.* 216, 121-132

16 14 Krebs, E.G. and Fischer, E.H. (1956) The phosphorylase b to a converting enzyme of rabbit
17 skeletal muscle. *Biochim. Biophys. Acta* 20, 150-157

18 15 Walsh, D.A., *et al.* (1968) An adenosine 3',5'-monophosphate-dependant protein kinase from
19 rabbit skeletal muscle. *J. Biol. Chem.* 243, 3763-3765

20 16 Cohen, P. (2002) The origins of protein phosphorylation. *Nat. Cell Biol.* 4, E127-E130

21 17 Steelman, L.S., *et al.* (2004) JAK//STAT, Raf//MEK//ERK, PI3K//Akt and BCR-ABL in cell cycle
22 progression and leukemogenesis. *Leukemia* 18, 189-218

1 18 The UniProt Consortium (2013) Update on activities at the Universal Protein Resource (UniProt)
2 in 2013. *Nucleic Acids Res.* 41, D43-D47

3 19 Manning, G., *et al.* (2002) The protein kinase complement of the human genome. *Science* 298,
4 1912-1934

5 20 Pennisi, E. (2012) ENCODE project writes eulogy for junk DNA. *Science* 337, 1159-1161

6 21 Knighton, D., *et al.* (1991) Crystal structure of the catalytic subunit of cyclic adenosine
7 monophosphate-dependent protein kinase. *Science* 253, 407-414

8 22 Tong, M. and Seeliger, M.A. (2015) Targeting conformational plasticity of protein kinases. *ACS*
9 *Chem. Biol.* 10, 190-200

10 23 Noble, M.E.M., *et al.* (2004) Protein kinase inhibitors: insights into drug design from structure.
11 *Science* 303, 1800-1805

12 24 Norman, R.A., *et al.* (2012) Structural approaches to obtain kinase selectivity. *Trends Pharmacol.*
13 *Sci.* 33, 273-278

14 25 Cox, K.J., *et al.* (2010) Tinkering outside the kinase ATP box: allosteric (type IV) and bivalent
15 (type V) inhibitors of protein kinases. *Future Med. Chem.* 3, 29-43

16 26 Lamba, V. and Ghosh, I. (2012) New directions in targeting protein kinases: focusing upon true
17 allosteric and bivalent inhibitors. *Curr. Pharm. Design* 18, 2936-2945

18 27 Yaish, P., *et al.* (1988) Blocking of EGF-dependent cell proliferation by EGF receptor kinase
19 inhibitors. *Science* 242, 933-935

20 28 Gazit, A., *et al.* (1989) Tyrphostins I: synthesis and biological activity of protein tyrosine kinase
21 inhibitors. *J. Med. Chem.* 32, 2344-2352

22 29 Gavrin, L.K. and Saiah, E. (2013) Approaches to discover non-ATP site kinase inhibitors.
23 *MedChemComm* 4, 41-51

1 30 Wang, Q., *et al.* (2014) Chapter two - a structural atlas of kinases inhibited by clinically
2 approved drugs. In *Methods Enzymol.* (Kevan, M.S., ed), pp. 23-67, Academic Press

3 31 Levitzki, A. (2013) Tyrosine kinase inhibitors: views of selectivity, sensitivity, and clinical
4 performance. *Annu. Rev. Pharmacol. Toxicol.* 53, 161-185

5 32 Druker, B.J., *et al.* (2001) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine
6 kinase in chronic myeloid leukemia. *N. Eng. J. Med.* 344, 1031-1037

7 33 Panjarian, S., *et al.* (2013) Structure and dynamic regulation of abl kinases. *J. Biol. Chem.* 288,
8 5443-5450

9 34 Winter, G.E., *et al.* (2012) Systems-pharmacology dissection of a drug synergy in imatinib-
10 resistant CML. *Nat. Chem. Biol.* 8, 905-912

11 35 Nagar, B., *et al.* (2002) Crystal structures of the kinase domain of c-Abl in complex with the
12 small molecule inhibitors PD173955 and imatinib (STI-571). *Cancer Res.* 62, 4236-4243

13 36 Lamontanara, A.J., *et al.* (2013) Mechanisms of resistance to BCR-ABL and other kinase
14 inhibitors. *Biochim. Biophys. Acta* 1834, 1449-1459

15 37 Ma, L., *et al.* (2014) A therapeutically targetable mechanism of BCR-ABL-independent imatinib
16 resistance in chronic myeloid leukemia. *Sci. Transl. Med.* 6, 252ra121

17 38 Levinson, N.M. and Boxer, S.G. (2014) A conserved water-mediated hydrogen bond network
18 defines bosutinib's kinase selectivity. *Nat. Chem. Biol.* 10, 127-132

19 39 Xuan, Y.-T., *et al.* (2001) An essential role of the JAK-STAT pathway in ischemic preconditioning.
20 *Proc. Natl. Acad. Sci. USA* 98, 9050-9055

21 40 Meyer, S.C. and Levine, R.L. (2014) Molecular pathways: molecular basis for sensitivity and
22 resistance to JAK kinase inhibitors. *Clin. Cancer Res.* 20, 2051-2059

1 41 Divito, S.J. and Kupper, T.S. (2014) Inhibiting Janus kinases to treat alopecia areata. *Nat. Med.*
2 20, 989-990

3 42 Doles, J.D. and Olwin, B.B. (2014) The impact of JAK-STAT signaling on muscle regeneration. *Nat.*
4 *Med.* 20, 1094-1095

5 43 Geyer, H.L. and Mesa, R.A. (2014) Therapy for myeloproliferative neoplasms: when, which
6 agent, and how? *Blood* 124, 3529-3537

7 44 Chrencik, J.E., *et al.* (2010) Structural and thermodynamic characterization of the TYK2 and
8 JAK3 kinase domains in complex with CP-690550 and CMP-6 *J. Mol. Biol.* 400, 413-433

9 45 Williams, N.K., *et al.* (2009) Dissecting specificity in the Janus kinases: the structures of JAK-
10 specific inhibitors complexed to the JAK1 and JAK2 protein tyrosine kinase domains. *J. Mol. Biol.*
11 387, 219-232

12 46 Goedken, E.R., *et al.* (2014) Tricyclic covalent inhibitors selectively target Jak3 through an
13 active-site thiol. *J. Biol. Chem.*, doi:10.1074/jbc.M11114.595181

14 47 Gehringer, M., *et al.* (2014) Novel hinge-binding motifs for Janus Kinase 3 inhibitors: a
15 comprehensive structure–activity relationship study on tofacitinib bioisosteres. *ChemMedChem* 9,
16 2516-2527

17 48 Hynes, N.E. and Lane, H.A. (2005) ERBB receptors and cancer: the complexity of targeted
18 inhibitors. *Nat. Rev. Cancer* 5, 341-354

19 49 Littlefield, P., *et al.* (2014) Structural analysis of the EGFR/HER3 heterodimer reveals the
20 molecular basis for activating HER3 mutations. *Sci. Signal.* 7, ra114

21 50 Citri, A. and Yarden, Y. (2006) EGF–ERBB signalling: towards the systems level. *Nat. Rev. Mol.*
22 *Cell Biol.* 7, 505-516

1 51 Yun, C.-H., *et al.* (2007) Structures of lung cancer-derived EGFR mutants and inhibitor
2 complexes: mechanism of activation and insights into differential inhibitor sensitivity. *Cancer Cell*
3 11, 217-227

4 52 Gajiwala, Ketan S., *et al.* (2013) Insights into the aberrant activity of mutant EGFR kinase
5 domain and drug recognition. *Structure* 21, 209-219

6 53 Stamos, J., *et al.* (2002) Structure of the epidermal growth factor receptor kinase domain alone
7 and in complex with a 4-anilinoquinazoline inhibitor (Erlotinib with EGFR). *J. Biol. Chem.* 277,
8 46265-46272

9 54 Wood, E.R., *et al.* (2004) A unique structure for epidermal growth factor receptor bound to
10 GW572016 (lapatinib): relationships among protein conformation, Inhibitor off-rate, and receptor
11 activity in tumor cells. *Cancer Res.* 64, 6652-6659

12 55 Qiu, C., *et al.* (2008) Mechanism of activation and inhibition of the HER4/ErbB4 kinase.
13 *Structure* 16, 460-467

14 56 Fang, Z., *et al.* (2013) Strategies for the selective regulation of kinases with allosteric
15 modulators: exploiting exclusive structural features. *ACS Chem. Biol.* 8, 58-70

16 57 Zhao, Z., *et al.* (2014) Exploration of type II binding mode: a privileged approach for kinase
17 inhibitor focused drug discovery? *ACS Chem. Biol.* 9, 1230-1241

18 58 Knowles, P.P., *et al.* (2006) Structure and chemical inhibition of the RET tyrosine kinase domain.
19 *J. Biol. Chem.* 281, 33577-33587

20 59 Ferrara, N., *et al.* (2003) The biology of VEGF and its receptors. *Nat. Med.* 9, 669-676

21 60 Olofsson, B., *et al.* (1996) Vascular endothelial growth factor B, a novel growth factor for
22 endothelial cells. *Proc. Natl. Acad. Sci. USA* 93, 2576-2581

1 61 McTigue, M., *et al.* (2012) Molecular conformations, interactions, and properties associated
2 with drug efficiency and clinical performance among VEGFR TK inhibitors. *Proc. Natl. Acad. Sci.*
3 *USA* 109, 18281-18289

4 62 Simard, J.R., *et al.* (2009) Development of a fluorescent-tagged kinase assay system for the
5 detection and characterization of allosteric kinase inhibitors. *J. Am. Chem. Soc.* 131, 13286-13296

6 63 Harris, P.A., *et al.* (2008) Discovery of 5-[[4-[(2,3-Dimethyl-2H-indazol-6-yl)methylamino]-2-
7 pyrimidinyl]amino]-2-methyl-benzenesulfonamide (Pazopanib), a novel and potent vascular
8 endothelial growth factor receptor inhibitor. *J. Med. Chem.* 51, 4632-4640

9 64 Okamoto, K., *et al.* (2015) Distinct binding mode of multikinase inhibitor lenvatinib revealed by
10 biochemical characterization. *ACS Med. Chem. Lett.* 6, 89-94

11 65 Chiarle, R., *et al.* (2008) The anaplastic lymphoma kinase in the pathogenesis of cancer. *Nat.*
12 *Rev. Cancer* 8, 11-23

13 66 Awad, M.M. and Shaw, A.T. (2014) ALK Inhibitors in non–small cell lung cancer: crizotinib and
14 beyond. *Clin. Adv. Hematol. Oncol.* 12, 429-439

15 67 Awad, M.M., *et al.* (2013) Acquired resistance to crizotinib from a mutation in CD74–ROS1. *N.*
16 *Eng. J. Med.* 368, 2395-2401

17 68 Cui, J.J., *et al.* (2011) Structure based drug design of crizotinib (PF-02341066), a potent and
18 selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic
19 lymphoma kinase (ALK). *J. Med. Chem.* 54, 6342-6363

20 69 Shaw, A.T., *et al.* (2014) Ceritinib in ALK-Rearranged non–small-cell lung cancer. *N. Eng. J. Med.*
21 370, 1189-1197

22 70 Friboulet, L., *et al.* (2014) The ALK inhibitor ceritinib overcomes crizotinib resistance in non-
23 small cell lung cancer *Cancer Discov.* 4, 662-673

1 71 Stamos, J., *et al.* (2004) Crystal structure of the HGF β - chain in complex with the Sema
2 domain of the Met receptor. *EMBO J.* 23, 2325-2335

3 72 Basilico, C., *et al.* (2008) A High Affinity Hepatocyte Growth Factor-binding Site in the
4 Immunoglobulin-like Region of Met. *J. Biol. Chem.* 283, 21267-21277

5 73 Trusolino, L., *et al.* (2010) MET signalling: principles and functions in development, organ
6 regeneration and cancer. *Nat. Rev. Mol. Cell Biol.* 11, 834-848

7 74 Gelsomino, F., *et al.* (2014) MET and small-cell lung cancer. *Cancers* 6, 2100-2115

8 75 Katayama, R., *et al.* (2015) Cabozantinib overcomes crizotinib resistance in ROS1 fusion positive
9 cancer. *Clin. Cancer Res.* 21, 166-174

10 76 Solca, F., *et al.* (2012) Target binding properties and cellular activity of afatinib (BIBW 2992), an
11 irreversible ErbB family blocker. *J. Pharmacol. Exp. Ther.* 343, 342-350

12 77 Hendriks, R.W., *et al.* (2014) Targeting Bruton's tyrosine kinase in B cell malignancies. *Nat. Rev.*
13 *Cancer* 14, 219-232

14 78 Byrd, J.C., *et al.* (2013) Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. *N.*
15 *Eng. J. Med.* 369, 32-42

16 79 Garber, K. (2014) Kinase inhibitors overachieve in CLL. *Nat. Rev. Drug Discov.* 13, 162-164

17 80 Marcotte, D.J., *et al.* (2010) Structures of human Bruton's tyrosine kinase in active and inactive
18 conformations suggest a mechanism of activation for TEC family kinases. *Protein Sci.* 19, 429-439

19 81 Bollag, G., *et al.* (2012) Vemurafenib: the first drug approved for BRAF-mutant cancer. *Nat. Rev.*
20 *Drug Discov.* 11, 873-886

21 82 Wan, P.T.C., *et al.* (2004) Mechanism of activation of the RAF-ERK signaling pathway by
22 oncogenic mutations of B-RAF. *Cell* 116, 855-867

1 83 Bollag, G., *et al.* (2010) Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-
2 mutant melanoma. *Nature* 467, 596-599

3 84 Pulici, M., *et al.* (2014) Optimization of diarylthiazole B-Raf inhibitors: identification of a
4 compound endowed with high oral antitumor activity, mitigated hERG inhibition, and low
5 paradoxical effect. *ChemMedChem* 10, 276-295

6 85 Luke, J.J., *et al.* (2014) The biology and clinical development of MEK inhibitors for cancer. *Drugs*
7 74, 2111-2128

8 86 Abe, H., *et al.* (2011) Discovery of a highly potent and selective MEK inhibitor: GSK1120212
9 (JTP-74057 DMSO solvate). *ACS Med. Chem. Lett.* 2, 320-324

10 87 Dong, Q., *et al.* (2011) Discovery of TAK-733, a potent and selective MEK allosteric site inhibitor
11 for the treatment of cancer. *Bioorg. Med. Chem. Lett.* 21, 1315-1319

12 88 Flaherty, K.T., *et al.* (2012) Combined BRAF and MEK inhibition in melanoma with BRAF V600
13 mutations. *N. Eng. J. Med.* 367, 1694-1703

14 89 Long, G.V., *et al.* (2014) Combined BRAF and MEK inhibition versus BRAF inhibition alone in
15 melanoma. *N. Eng. J. Med.* 371, 1877-1888

16 90 Wu, P. and Hu, Y.Z. (2010) PI3K/Akt/mTOR pathway inhibitors in cancer: a perspective on
17 clinical progress. *Curr. Med. Chem.* 17, 4326-4341

18 91 Chiarini, F., *et al.* (2015) Current treatment strategies for inhibiting mTOR in cancer. *Trends*
19 *Pharmacol. Sci.* 36, 124-135

20 92 Choi, Y.J. and Anders, L. (2014) Signaling through cyclin D-dependent kinases. *Oncogene* 33,
21 1890-1903

22 93 Casimiro, M.C., *et al.* (2014) Overview of cyclins D1 function in cancer and the CDK inhibitor
23 landscape: past and present. *Expert Opin. Investig. Drugs* 23, 295-304

1 94 Lu, H. and Schulze-Gahmen, U. (2006) Toward understanding the structural basis of Cyclin-
2 Dependent Kinase 6 specific inhibition. *J. Med. Chem.* 49, 3826-3831

3 95 Whitman, M., *et al.* (1985) Association of phosphatidylinositol kinase activity with polyoma
4 middle-T competent for transformation. *Nature* 315, 239-242

5 96 Wu, P., *et al.* (2009) PI3K inhibitors for cancer therapy: what has been achieved so far? *Curr.*
6 *Med. Chem.* 16, 916-930

7 97 Furman, R.R., *et al.* (2014) Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. *N.*
8 *Eng. J. Med.* 370, 997-1007

9 98 Cheson, B.D. (2014) CLL and NHL: the end of chemotherapy? *Blood* 123, 3368-3370

10 99 Ali, K., *et al.* (2014) Inactivation of PI(3)K p110delta breaks regulatory T-cell-mediated immune
11 tolerance to cancer. *Nature* 510, 407-411

12 100 Berndt, A., *et al.* (2010) The p110[delta] structure: mechanisms for selectivity and potency of
13 new PI(3)K inhibitors. *Nat. Chem. Biol.* 6, 117-124

14 101 Somoza, J.R., *et al.* (2015) Structural, biochemical and biophysical characterization of Idelalisib
15 binding to phosphoinositide 3-kinase delta. *J. Biol. Chem.*, doi: 10.1074/jbc.M1114.634683

16 102 Wu, P. and Hu, Y. (2012) Small molecules targeting phosphoinositide 3-kinases.
17 *MedChemComm* 3, 1337-1355

18 103 Flinn, I.W., *et al.* (2014) Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase- δ , as
19 therapy for previously treated indolent non-Hodgkin lymphoma. *Blood* 123, 3406-3413

20 104 Brown, J.R., *et al.* (2014) Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110 δ , for
21 relapsed/refractory chronic lymphocytic leukemia. *Blood* 123, 3390-3397

22 105 Fruman, D.A. and Rommel, C. (2014) PI3K and cancer: lessons, challenges and opportunities.
23 *Nat. Rev. Drug Discov.* 13, 140-156

1 106 Costa, C., *et al.* (2015) Measurement of PIP3 levels reveals an unexpected role for p110 β in
2 early adaptive responses to p110 α -specific inhibitors in luminal breast cancer. *Cancer Cell* 27, 97-
3 108

4 107 Schwartz, S., *et al.* (2015) Feedback suppression of PI3K α signaling in PTEN-mutated tumors is
5 relieved by selective inhibition of PI3K β . *Cancer Cell* 27, 109-122

6 108 Kinch, M.S. (2014) An analysis of FDA-approved drugs for oncology. *Drug Discov. Today* 19,
7 1831-1835

8 109 Davis, M.I., *et al.* (2011) Comprehensive analysis of kinase inhibitor selectivity. *Nat. Biotech.*
9 29, 1046-1051

10 110 Rask-Andersen, M., *et al.* (2014) The druggable genome: evaluation of drug targets in clinical
11 trials suggests major shifts in molecular class and indication. *Annu. Rev. Pharmacol. Toxicol.* 54, 9-
12 26

1 **Figure legend**

2 [Figure 1]

3 **Figure 1.** Kinase structure and different types of reversible small molecule kinase inhibitors. **(A)** Co-
4 crystal structure of PDK1 with ATP (adenine and ribose in green backbone, phosphate groups in
5 orange) with the enlarged area showing the structural elements around the ATP binding site.
6 Hydrogen bonds in red dotted lines, hinge region and hinge residues in green backbone, P-loop
7 and P-loop residue in brown orange backbone, the aspartate residue of the DFG motif and the
8 activation loop in white backbone (PDB ID: 4RRV, 1.41 Å). **(B)** Four types of reversible binding
9 modes: type I inhibitors bind to the active conformation of kinase with the aspartate residue
10 (white backbone) of the DFG motif pointing into the ATP-binding pocket; type II inhibitors bind
11 and stabilize the inactive conformation of kinase with the flipped aspartate residue facing outward
12 of the binding pocket; type III inhibitors occupy an allosteric pocket that is adjacent to the ATP
13 binding pocket but does not overlap with it; type IV inhibitors bind to an allosteric pocket remote
14 from the ATP binding pocket.

15 [Figure 2]

16 **Figure 2.** FDA approved small molecule kinase inhibitors (as of March 2015).

17 [Figure 3]

18 **Figure 3.** Type II inhibitors of BCR-Abl. **(A)** Chemical structure of imatinib and its depicted binding
19 mode with BCR-Abl. **(B)** Imatinib co-crystal structure (PDB ID: 1IEP, 2.10 Å). **(C)** Chemical structure
20 of nilotinib and its depicted binding mode with BCR-Abl. **(D)** Nilotinib co-crystal structure (PDB ID:
21 3CS9, 2.21 Å). **(E)** Chemical structure of ponatinib and its depicted binding mode with BCR-Abl. **(F)**

1 Ponatinib co-crystal structure with wild-type BCR-Abl (PDB ID: 3OXZ, 2.20 Å). Small molecule
2 inhibitors are shown in magenta backbone, hydrogen bonds are indicated by red dotted lines, and
3 residues that interact with inhibitors through hydrogen bonds are shown in green backbone, and
4 π -interactions formed between certain aromatic rings of these molecules and residues including
5 Phe and Tyr are not illustrated in these ribbon-show figures. Co-crystal structures of ponatinib
6 (PDB ID: 3IK3, 1.9 Å) and its analogue (PDB ID: 3OY3, 1.95 Å) with mutant T315I (shown in yellow
7 backbone in F) BCR-Abl have also been released.

8 [Figure 4]

9 **Figure 4.** Inhibitors binding with active BCR-Abl. (A) Chemical structure of dasatinib and its
10 depicted binding mode with BCR-Abl. (B) dasatinib co-crystal structure (PDB ID: 2GQG, 2.40 Å). (C)
11 Surface show of the dasatinib-Abl co-crystal structure (PDB ID: 2GQG, 2.40 Å). (D) Chemical
12 structure of bosutinib and its depicted binding mode with BCR-Abl. (E) Bosutinib co-crystal
13 structure (PDB ID: 3UE4, 2.42 Å). (F) Surface show of the bosutinib-Abl co-crystal structure (PDB ID:
14 2GQG, 2.40 Å). Small molecule inhibitors are shown in magenta backbone, hydrogen bonds are
15 indicated by red dotted lines, residues that interact with inhibitors through hydrogen bonds are
16 shown in green backbone, the gate-keeper residue is shown in yellow backbone, and residues of
17 the DFG motif are shown in white backbones.

18 [Figure 5]

19 **Figure 5.** JAK inhibitors. (A) Chemical structure of ruxolitinib. (B) Chemical structure of tofacitinib
20 and its depicted binding mode with JAK2/3. (C) Tofacitinib co-crystal structure with JAK3 (PDB ID:
21 3LXK 2.0 Å). (D) Tofacitinib co-crystal structure with JAK2 (PDB ID: 3FUP 2.4 Å). Tofacitinib shown

1 in magenta backbone, hydrogen bonds are indicated by red dotted lines, and residues that
2 interact with tofacitinib through hydrogen bonds are shown in green backbone.

3 [Figure 6]

4 **Figure 6.** Small molecule kinase inhibitors against ErbBs. **(A)** Chemical structure of gefitinib and its
5 depicted binding mode with EGFR. **(B)** Gefitinib co-crystal structure with wild type EGFR (PDB ID:
6 2ITY, 3.42 Å). **(C)** Gefitinib co-crystal structure with mutant L858R+T790M+V948R EGFR (PDB ID:
7 4I22, 1.71 Å). **(D)** Chemical structure of erlotinib and its depicted binding mode with EGFR. **(E)**
8 Erlotinib co-crystal structure with EGFR (PDB ID: 1M17, 2.60 Å). **(F)** Surface show of erlotinib co-
9 crystal structure with EGFR (PDB ID: 1M17, 2.60 Å). **(G)** Chemical structure of lapatinib and its
10 depicted binding mode with EGFR. **(H)** Lapatinib co-crystal structure with EGFR (PDB ID: 1XKK, 2.40
11 Å). **(I)** Lapatinib-ErbB4 complex, the methylsulfonylethanylaminoethylfuranyl moiety is not
12 shown in this crystal structure (PDB ID: 3BBT, 2.80 Å). **(J)** Chemical structure of vandetanib and its
13 depicted binding mode with RET. **(K)** Vandetanib co-crystal structure with RET (PDB ID: 2IVU, 2.50
14 Å). **(L)** Surface show of vandetanib co-crystal structure with RET (PDB ID: 2IVU, 2.50 Å). Small
15 molecule inhibitors are shown in magenta backbone, hydrogen bonds are indicated by red dotted
16 lines, residues that interact with inhibitors through hydrogen bonds are shown in green backbone,
17 residue 858 and residue 790 in the gefitinib-EGFR complex are shown in yellow backbone, and
18 residues of the DFG-motif are shown in white backbone.

19 [Figure 7]

20 **Figure 7.** Small molecule kinase inhibitors binding to VEGFR. **(A)** Chemical structure of sorafenib
21 and its depicted binding mode with VEGFR2. **(B)** Sorafenib co-crystal structure with VEGFR2 (PDB

1 ID: 4ASD, 2.03 Å). (C) Chemical structure of sunitinib and its depicted binding mode with VEGFR2.
2 (D) Sunitinib co-crystal structure with VEGFR2 (PDB ID: 4AGD, 2.81 Å). (E) Chemical structure of
3 axitinib and its depicted binding mode with VEGFR2. (F) Axitinib co-crystal structure with VEGFR2
4 (PDB ID: 4AG8, 1.95 Å). (G) Chemical structure of nintedanib and its depicted binding mode with
5 VEGFR2. (H) Nintedanib co-crystal structure with VEGFR2 (PDB ID: 3C7Q, 2.10 Å). (I) Chemical
6 structure of regorafenib. (J) Chemical structure of pazopanib and its proposed binding mode with
7 VEGFR2 based on crystal structure of PDB ID: 3CJG (2.25 Å). (K) Chemical structure of lenvatinib
8 and its depicted binding mode with VEGFR2. Small molecule inhibitors are shown in magenta
9 backbone, hydrogen bonds are indicated by red dotted lines, and residues that interact with
10 inhibitors through hydrogen bonds are shown in green backbone.

11 [Figure 8]

12 **Figure 8.** Small molecule kinase inhibitors binding to ALK. (A) Chemical structure of crizotinib and
13 its depicted binding mode with ALK. (B), (C) Crizotinib co-crystal structure with ALK (PDB ID: 2XP2,
14 1.9 Å). (D) Chemical structure of ceritinib and its depicted binding mode with ALK. (E), (F) Ceritinib
15 co-crystal structure with ALK (PDB ID: 4MKC, 2.01 Å). Small molecule inhibitors are shown in
16 magenta backbone, hydrogen bonds are indicated by red dotted lines, residues that interact with
17 inhibitors through hydrogen bonds are shown in green backbone, and residues of the DGF motif
18 are shown in white backbone.

19 [Figure 9]

20 **Figure 9.** Small molecule kinase inhibitors binding to MET. (A) Depicted binding mode of crizotinib
21 with MET. (B), (C) Crizotinib co-crystal structure with MEK (PDB ID: 2WGJ, 2.0 Å). (D) Chemical

1 structure of cabozantinib. (E) Chemical structure of compound DWF (name derived from PDB
2 ligand identifier code) and its depicted binding mode with MET. (F, G) Cabozantinib co-crystal
3 structure with MET (PDB ID: 4MXC, 1.63 Å). Small molecule inhibitors are shown in magenta
4 backbone, hydrogen bonds are indicated by red dotted lines, residues that interact with inhibitors
5 through hydrogen bonds are shown in green backbone, and the Asp residue of the DGF motif is
6 shown in white backbone.

7 [Figure 10]

8 **Figure 10.** Binding mode of irreversible small molecule kinase inhibitors. (A) Chemical structure of
9 afatinib and its depicted binding mode with EGFR. (B) Afatinib co-crystal structure with wildtype
10 EGFR (PDB ID: 4G5J, 2.80 Å). (C) Afatinib co-crystal structure with mutant T790M EGFR (PDB ID:
11 4G5P, 3.17 Å). (D) Chemical structure of ibrutinib and its proposed binding mode with BTK. (E)
12 Chemical structure of compound B43 and its depicted binding mode with BTK. (F) B43 co-crystal
13 structure with BTK (PDB ID: 3GEN, 1.60 Å). Wild type and mutant residue790 of EGFR is shown in
14 yellow backbone, small molecule inhibitors are shown in magenta backbone, hydrogen bonds are
15 indicated by red dotted lines, residues that interact with inhibitors through hydrogen bonds are
16 shown in green backbone, covalent bonds are indicated by purple solid lines, and the cysteine
17 residue contributing to the formation of a covalent bond is shown in purple backbone.

18 [Figure 11]

19 **Figure 11.** Structures of approved small molecule kinase inhibitors binding to serine/threonine
20 kinase B-Raf. (A) Chemical structure of vemurafenib and its depicted binding mode with mutant
21 V600E B-Raf kinase. (B) Vemurafenib co-crystal structure with V600E B-Raf (PDB ID: 3OG7, 2.45 Å).

1 (C) Surface show of the vemurafenib-V600E B-Raf complex with the residues of the DFG motif
2 highlighted in white backbones (PDB ID: 3OG7, 2.45 Å). (D) Chemical structure of dabrafenib. (E)
3 Chemical structure of the dabrafenib derivative compound 20 and its depicted binding mode with
4 mutant V600E B-Raf. (F) Compound **20** co-crystal structure with V600E B-Raf (PDB ID: 4CQE, 2.30
5 Å). (G) Chemical structure of sorafenib and its depicted binding mode with wild type B-Raf. (H)
6 Sorafenib co-crystal structure with wild type B-Raf (PDB ID: 1UWH, 2.95 Å). (I) Sorafenib co-crystal
7 structure with mutant V599E B-Raf, mutated residue Glu599 is shown in brown backbone (PDB ID:
8 1UWJ, 3.5 Å). Small molecule inhibitors are shown in magenta backbone, hydrogen bonds are
9 indicated by red dotted lines, and residues that interact with inhibitors through hydrogen bonds
10 are shown in green backbone.

11 [Figure 12]

12 **Figure 12.** MEK kinase inhibitor binding mode. (A) Chemical structure of trametinib. (B) Chemical
13 structure of Tak-733 and its depicted binding mode with MEK1. (C) Tak-733 co-crystal structure
14 with MEK1 (PDB ID: 3PP1, 2.70 Å). ATP is shown in cyan backbone, Tak-733 in magenta backbone,
15 hydrogen bonds are indicated by red dotted lines, and residues that interact with ATP and Tak-733
16 through hydrogen bonds are shown in green backbone.

17 [Figure 13]

18 **Figure 13.** CDK inhibitor palbociclib. (A) Chemical structure of palbociclib and its depicted binding
19 mode with CDK6. (B), (C) Palbociclib co-crystal structure with CDK6 (PDB ID: 2EUF, 3.0 Å).
20 Palbociclib is shown in magenta backbone, hydrogen bonds are indicated by red dotted lines,

1 residues that interact with inhibitors through hydrogen bonds are shown in green backbone, and
2 residues of the DFG motif are shown in white backbones.

3 [Figure 14]

4 **Figure 14.** PI3K δ inhibitor idelalisib. (A) Chemical structure of idelalisib and its depicted binding
5 mode with PI3K δ . (B), (C) Idelalisib co-crystal structure with PI3K δ (PDB ID: 4XE0, 2.43 Å). Idelalisib
6 is shown in magenta backbone, hydrogen bond is indicated by a red dotted line, and residues of
7 the DFG motif are shown in white backbones.